Sign In

Jean-Philippe Combal

Co-Founder & Chief Executive Officer of Vivet Therapeutics, SpliceBio SL. Chairman, Board of Directors,

Jean-Philippe Combal is a highly accomplished individual with a strong educational background and extensive experience in the pharmaceutical industry. He holds degrees from renowned institutions such as INSEAD, ESCP Business School, and Paris-Sud University (Paris XI). Jean-Philippe has a solid foundation, with an ex-MBA in General Management, a Master's in Pharmaceuticals Strategic Marketing, and a Pharm.D and Ph.D in Pharmaceutical sciences.

Highlights

Dec 21 · linkedin

I am heading to San Francisco for #JPM24! Let's make the most of this opportunity. Please send a message if you would like to schedule a meetup: [email protected]. #Wilsonsdisease #genetherapy #innovation #letsconnect

Nov 30 · linkedin

The Vivet Therapeutics team had the honor of sponsoring and attending the Spanish Wilson’s Disease Association meeting in Valencia, Spain (learn more: https://lnkd.in/eUMB-AUw ) over the last weekend. It is always insightful and inspirational to engage with the patient community and key thought leaders devoted to improving outcomes for those living with Wilson’s Disease. At Vivet we will continue our relentless focus on our Phase 2 gene therapy study and continue to engage, learn and evolve through these important patient advocacy meetings.   Key Takeaways: 1-Multidisciplinary teams, notably including hepatologists and neurologists, are necessary to optimize patient care, ideally in specialized reference centers. 2- The development of child-friendly medications is an urgent demand among patients' families. 3- Early diagnosis, newborn screening, and improved education involving Patient Advocacy Groups (PAG) are crucial to prevent misdiagnosis and ensure better treatment adherence, which can have significant consequences, especially in cases of neurological and acute liver failure. 4- Wilson Disease and pregnancy are fully compatible with continued treatment and closer monitoring. 5- Epidemiological data and registries must gather information from various countries and be compared with real-world data, notably regarding complications, mortality, and compliance. 6- Innovative treatment modalities are investigated, including gene therapy (first data expected in 2024) and new chelating approaches.   #genetherapy #patientadvocacy #rarediseases Sonia VALERO, Bernard Bénichou Veronica Ferrer Gloria Gonzalez-Aseguinolaza

Related Questions

What are Jean-Philippe Combal's key achievements at Vivet Therapeutics?
How did Jean-Philippe Combal contribute to the development of products at Fovea?
What is the significance of the AAV-intein gene therapy platform at Splice Bio?
What are the main goals of Splice Bio under Jean-Philippe Combal's leadership?
How does Jean-Philippe Combal's experience compare to other biotech executives?
Jean-Philippe Combal
Jean-Philippe Combal, photo 1
Jean-Philippe Combal, photo 2
Add to my network

Location

Paris, Île-de-France, France